Investigation announced for Investors in shares of Takeda Pharmaceutical Company Limited (NYSE: TAK)

An investigation was announced concerning potential securities laws violations by Takeda Pharmaceutical Company Limited in connection with certain financial statements.

Investors who purchased shares of Takeda Pharmaceutical Company Limited (NYSE: TAK), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Takeda Pharmaceutical Company Limited (NYSE: TAK) concerning whether a series of statements by Takeda Pharmaceutical Company regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Japan based Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products.
On May 8, 2018, Shire plc (NASDAQ: SHPG) and Takeda Pharmaceutical Company Limited (“Takeda”) announced that they reached agreement on the terms of a recommended offer pursuant to which Takeda Pharmaceutical Company Limited will acquire the entire issued and to be issued ordinary share capital of Shire plc. Under the terms of the transaction, Shire shareholders will receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire they own.

Takeda Pharmaceutical Company Limited reported that its Total Revenue rose from over 1.77 billion JPY for the 12 months period that ended on March 31, 2018 to over 2.97 billion JPY for the 12 months period that ended on March 31, 2019 and that its Net Income over those respective time periods declined from 186.88 million JPY to 109,12 million JPY.

On May 14, 2019, Takeda Pharmaceutical Company Limited forecast an unexpected operating loss for the current year, citing costs associated with the Company's $59 billion purchase of Shire Plc.

Shares of Takeda Pharmaceutical Company Limited (NYSE: TAK) declined from $30.79 per share in January 2018 to as low as $16.46 per share on June 6, 2019.

Those who purchased shares of Takeda Pharmaceutical Company Limited (NYSE: TAK) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.